WEX vs TGTX Comparison

WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.